GLP-1 receptor agonists can cause a specific kind of mental clouding. People describe it as a fog that settles over thinking and memory. This article compares two research peptides that may address that fog. P21 and Selank both appear in studies on cognitive repair. They work through different pathways in the brain. Understanding those pathways helps explain why they might be combined. NAD+ is a coenzyme that supports cellular energy. It often appears alongside these peptides in longevity research.

This article does not recommend personal use of any compound. It summarizes published research for educational purposes. The discussion below is intended for individuals familiar with reading and interpreting biomedical research.

Why compare P21 and Selank

GLP-1 drugs reduce appetite and slow stomach emptying. They also change how the brain processes reward and satiety signals. Some users report a side effect called cognitive fog. This fog includes poor recall and slow word finding. A 2023 review of GLP-1 side effects noted that cognitive complaints are underreported. Both P21 and Selank have been studied for cognitive enhancement. They are not approved medications. They are research peptides with different mechanisms.

P21 is a small peptide derived from a larger protein called CNTF. CNTF stands for ciliary neurotrophic factor. It supports the survival of neurons. Selank is a synthetic peptide based on a natural immune protein. That protein is called tuftsin. Selank influences anxiety and cognitive processing through immune and neurotransmitter pathways. Comparing them side by side shows where each might fit.

P21 profile

P21 is a 21-amino acid peptide. It was designed to mimic the neuroprotective effects of CNTF without CNTF's side effects. Published research shows that P21 can enhance learning and memory in animal models. A 2019 study found that P21 increased neurogenesis in the hippocampus. The hippocampus is a brain region critical for forming new memories. Neurogenesis means the birth of new neurons. More new neurons can improve cognitive flexibility.

P21 also appears to reduce inflammation in the brain. Chronic inflammation can cause brain fog. GLP-1 drugs reduce systemic inflammation. But some researchers think the rapid metabolic changes from GLP-1 drugs might temporarily disrupt brain energy balance. P21 may help neurons adapt to that change. The literature on P21 suggests it works through the BDNF pathway. BDNF is brain-derived neurotrophic factor. It helps neurons grow and connect. P21 increases BDNF expression in the hippocampus and cortex.

One internal article covers P21 for cognitive deficits in alcohol use disorder. That article explains how P21's neurogenic effects might reverse damage from chronic alcohol exposure. Another article discusses P21 and NAD+ for cognitive longevity. That piece reviews FDA peptide reassessment and how NAD+ might amplify P21's effects.

Selank profile

Selank is a heptapeptide. That means it has seven amino acids. It was developed in Russia and is used in some countries as an anxiolytic. Anxiolytic means anxiety-reducing. Selank does not cause sedation like benzodiazepines. It works by modulating the expression of genes involved in neurotransmitter balance. A 2020 study showed that Selank increases brain-derived neurotrophic factor in the hippocampus. It also increases expression of genes for GABA and dopamine receptors.

Selank's main effect is on anxiety and emotional regulation. GLP-1 users sometimes report increased anxiety during weight loss. That anxiety can worsen cognitive fog. Selank may reduce that anxiety. It also has direct cognitive effects. A 2018 trial in healthy volunteers found that Selank improved attention and memory after a single dose. The effect was modest but measurable. Selank appears to stabilize the blood-brain barrier. A stable barrier prevents inflammatory molecules from entering the brain. That may reduce fog caused by metabolic shifts.

For a direct look at Selank's role in GLP-1 anxiety, see Selank for GLP-1-induced anxiety during weight loss. That article reviews user reports and preclinical data on how Selank calms the nervous system without sedation.

Head-to-head evidence

No published clinical trial directly compares P21 and Selank in humans. Most P21 research is in rodents. Selank has more human data because it is approved in Russia for anxiety. A 2022 review of peptide nootropics noted that P21 and Selank have complementary mechanisms. P21 promotes neuronal growth and repair. Selank modulates neurotransmitter balance and reduces anxiety. Combining them might address both the structural and chemical causes of cognitive fog.

GLP-1-induced cognitive fog likely has multiple causes. One cause is reduced glucose availability to the brain during rapid weight loss. Another cause is altered gut-brain signaling. A third cause is increased stress hormones during caloric restriction. P21 may help neurons survive low glucose conditions. Selank may reduce the stress response. Together they could cover more ground than either alone.

NAD+ is a coenzyme involved in cellular energy production. It declines with age and metabolic stress. GLP-1 drugs increase insulin sensitivity and may raise NAD+ levels indirectly. But some researchers suggest supplementing NAD+ precursors during GLP-1 therapy. NAD+ supports mitochondrial function in neurons. Mitochondria are the power plants of cells. Better mitochondrial function means more energy for thinking. A 2021 study in mice showed that NAD+ precursors improved cognitive performance in a model of diet-induced obesity. P21 and Selank do not directly raise NAD+. But they may work better when NAD+ levels are adequate.

For a detailed look at how P21 and NAD+ interact, see P21 and NAD+ for cognitive longevity. That article explains the FDA's peptide reassessment and why NAD+ is often stacked with P21.

Where each is studied more

P21 has a stronger evidence base for neurogenesis and neuroprotection. It is studied in models of Alzheimer's disease, traumatic brain injury, and alcohol-induced cognitive decline. Selank has a stronger evidence base for anxiety and stress-related cognitive impairment. It is studied in models of generalized anxiety, post-traumatic stress, and attention deficit. Neither peptide has been specifically tested against GLP-1-induced cognitive fog. That is a gap in the literature.

Researchers interested in GLP-1 side effects might look to these peptides as potential adjuncts. But no clinical guidelines exist. The only way to know if they help is through controlled trials. Until then, the evidence is preclinical and indirect. Readers should consult a qualified clinician before considering any compound discussed in this article.

Common questions

Can P21 and Selank be taken together?

There is no published human trial testing the combination. Preclinical data suggest they have different mechanisms. P21 promotes neuronal growth through BDNF. Selank modulates GABA and dopamine. Combining them might be redundant or additive. Without human data, no one can say if the combination is safe or effective. Animal studies would be the next logical step. Researchers sometimes combine peptides with different targets to test synergy. But that is a research question, not a clinical recommendation.

Does NAD+ help with GLP-1 brain fog?

NAD+ is a coenzyme that declines with age and metabolic stress. GLP-1 drugs change metabolism rapidly. That may temporarily lower brain NAD+ levels. NAD+ precursors like nicotinamide riboside have been shown to improve cognitive function in animal models of obesity. A 2021 mouse study found that NAD+ supplementation reversed cognitive deficits caused by a high-fat diet. Human data is limited but growing. NAD+ is not a direct treatment for brain fog. It supports the cellular machinery that keeps neurons working. That support might reduce fog caused by energy deficits.

Is Selank safer than P21?

Safety profiles differ because the compounds have different origins and histories. Selank has been used in humans for decades in Russia. It has a low reported rate of side effects. P21 is newer and has less human data. Most P21 research is in rodents. That does not mean P21 is unsafe. It means less is known about its long-term effects in humans. Both are research peptides. Neither is approved by the FDA for any indication. Safety cannot be assumed from animal studies alone.

Treatment of any condition is outside the scope of this article. Diagnosis and care should be conducted by a licensed practitioner.